A double-blind, stratified, randomised, parallel, placebo-controlled, multi-center study to assess the efficacy and safety of duloxetine (20mg bid for 2 weeks escalating to 40mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women greater than or equal to 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence

Trial Profile

A double-blind, stratified, randomised, parallel, placebo-controlled, multi-center study to assess the efficacy and safety of duloxetine (20mg bid for 2 weeks escalating to 40mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women greater than or equal to 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Mixed incontinence; Stress incontinence
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Sep 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004082).
    • 24 Aug 2006 Status change
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top